Zhang et al. also reported a DT of 127 ± 48 days for triple‐negative breast cancer, 184 ± 71 days for HER2+ breast cancer, and 257 ± 185 days for luminal A breast cancer (p = 0.013).19 This evidence concerns the gene ERBB2 and breast cancer.